Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07447713 · ClinicalTrials.gov registry record
Reference Range Study for the Quantra System With the QPlus Cartridge in Pediatric Patients
A clinical trial, sponsored by HemoSonics.
- Not yet
- Registry status
- 240
- Enrollment target
NCT07447713: Clinical Trial study, sponsored by HemoSonics.
NCT07447713 is a clinical trial that has not yet begun recruiting, run by HemoSonics. The registered enrollment target is 240 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07447713 has not yet begun recruiting, sponsored by HemoSonics.
- NOT YET RECRUITING
- Registry status
- 240 participants
- Enrollment target
Study Summary
This study will determine reference range intervals for the parameters reported by the Quantra System with the QPlus Cartridge in pediatric patients.
Primary Outcome
Reference range intervals for CT in pediatric patients
Interventions
- DIAGNOSTIC_TEST Quantra System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2026-04-15 |
| Est. Completion | 2027-05-30 |
What is known before NCT07447713 opens enrollment
NCT07447713 is an observational study that tracks outcomes without assigning an intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Quantra System is the first listed.
NCT07447713 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07447713 about?
NCT07447713 is a clinical study titled "Reference Range Study for the Quantra System With the QPlus Cartridge in Pediatric Patients". This study will determine reference range intervals for the parameters reported by the Quantra System with the QPlus Cartridge in pediatric patients.
What is the current status of trial NCT07447713?
This trial is currently not yet recruiting. The enrollment target is 240 participants. The study started on 2026-04-15. Estimated completion is 2027-05-30.
What interventions are being tested in trial NCT07447713?
The interventions under investigation include: Quantra System (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07447713?
This trial is sponsored by HemoSonics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI